MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$5,522,000
EPS
-$0.18
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenue-Revenue
---0
Total revenue-Other Revenue
---0
Total revenue
--45,000* 90,000 0
Research and development, net of reimbursements
4,201,000 7,433,500* 4,248,000 4,879,000
General and administrative
1,702,000 8,976,000* 1,534,000 2,624,000
Total operating expenses
5,903,000 16,409,500* 5,782,000 7,503,000
Loss from operations
-5,903,000 -16,454,500* -5,692,000 -7,503,000
Interest income - net
381,000 581,000 561,000 625,000
Total other income
381,000 581,000* 561,000 625,000
Net loss
-5,522,000 -15,873,500 -5,131,000 -6,878,000
Basic EPS
-0.18 -0.509 -0.16 -0.22
Diluted EPS
-0.18 -0.509 -0.16 -0.22
Basic Average Shares
31,237,681 31,195,891 31,195,891 31,195,891
Diluted Average Shares
31,237,681 31,195,891 31,195,891 31,195,891
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest income - net$381,000 Net loss-$5,522,000 Total other income$381,000 Loss from operations-$5,903,000 Total operatingexpenses$5,903,000 Research anddevelopment, net of...$4,201,000 General andadministrative$1,702,000

Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals, Inc. (ATNM)